A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VCT220 Tablets in Overweight/obese Subjects
Latest Information Update: 27 Dec 2024
Price :
$35 *
At a glance
- Drugs VCT 220 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Vincentage Pharma
- 23 Dec 2024 Results presented in a Corxel Pharmaceuticals Media Release.
- 02 Sep 2024 New trial record